There is now a vast body of literature on MRSA and CA-MRSA; the following is a sample of especially relevant recent publications on MRSA and related topics. Any article can most easily be retrieved in PubMed by searching with the PMID number.

​

1. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility.

Daum RS, Gupta S, Sabbagh R, Milewski WM.

J Infect Dis. 1992 Nov;166(5):1066-72. PMID: 1402017

 

2. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.

Desbois AP, Gemmell CG, Coote PJ.

Int J Antimicrob Agents. 2010 Mar 3. PMID: 20206480

 

3. Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents.

Chakraborty SP, Sahu SK, Mahapatra SK, Santra S, Bal M, Roy S, Pramanik P.

Nanotechnology. 2010 Mar 12;21(10):105103. PMID: 20154376

 

4. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?

Hazlewood KA, Brouse SD, Pitcher WD, Hall RG.

Am J Med. 2010 Feb;123(2):182.e1-7. Review. PMID: 20103028

 

5. In vitro activity of Inula helenium against clinical Staphylococcus aureus strains including MRSA.

O'Shea S, Lucey B, Cotter L.

Br J Biomed Sci. 2009;66(4):186-9. PMID: 20095126

 

6. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients.

Hill RL, Kearns AM, Nash J, North SE, Pike R, Newson T, Woodford N, Calver R, Livermore DM.

J Antimicrob Chemother. 2010 Mar;65(3):442-5. Epub 2010 Jan 20. PMID: 20089543

 

7. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication.

Boucher HW.

Clin Infect Dis. 2010 Jan 1;50 Suppl 1:S4-9. PMID: 20067391

 

8. Vancomycin treatment failure in a vancomycin susceptible methicillin-resistant Staphylococcus aureus (MRSA) infected patient.

Norazah A, Salbiah N, Nurizzat M, Santhana R.

Med J Malaysia. 2009 Jun;64(2):166-7. PMID: 20067391

 

9. Recombination between ccrC genes in a type V (5C2&5) staphylococcal cassette chromosome mec (SCCmec) of Staphylococcus aureus ST398 leads to conversion from methicillin resistance to methicillin susceptibility in vivo.

Chlebowicz MA, Nganou K, Kozytska S, Arends JP, Engelmann S, Grundmann H, Ohlsen K, van Dijl JM, Buist G.

Antimicrob Agents Chemother. 2010 Feb;54(2):783-91. Epub 2009 Dec 7. PMID: 19995931

 

10. Extranasal methicillin-resistant Staphylococcus aureus colonization at admission to an acute care Veterans Affairs hospital.

Baker SE, Brecher SM, Robillard E, Strymish J, Lawler E, Gupta K.

Infect Control Hosp Epidemiol. 2010 Jan;31(1):42-6. PMID: 19954335

 

11. Do guidelines for the prevention and control of methicillin-resistant Staphylococcus aureus make a difference?

Humphreys H.

Clin Microbiol Infect. 2009 Dec;15 Suppl 7:39-43. Review. PMID: 19951333

 

12. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection.

Ferry T, Uçkay I, Vaudaux P, François P, Schrenzel J, Harbarth S, Laurent F, Bernard L, Vandenesch F, Etienne J, Hoffmeyer P, Lew D.

Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):171-80. Epub 2009 Nov 28. PMID: 19946789

 

13. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.

Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF.

Antimicrob Agents Chemother. 2010 Feb;54(2):610-3. Epub 2009 Nov 16. PMID: 19917746

 

14. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection.

Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD.

PLoS One. 2009 Nov 12;4(11):e7804. PMID: 19915659

 

15. Contemporary management of and outcomes from cardiac device related infections.

Margey R, McCann H, Blake G, Keelan E, Galvin J, Lynch M, Mahon N, Sugrue D, O'Neill J.

Europace. 2010 Jan;12(1):64-70. Epub . PMID: 19910314

 

16. Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit.

Skrupky LP, Micek ST, Kollef MH.

Crit Care. 2009;13(5):222. Epub 2009 Oct 8. PMID: 19889197

 

17. Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus?

Lee BY, Tsui BY, Bailey RR, Smith KJ, Muder RR, Lewis GJ, Harrison LH.

Infect Control Hosp Epidemiol. 2009 Dec;30(12):1158-65. PMID: 19852665

 

18. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.

Bae IG, Federspiel JJ, Miró JM, Woods CW, Park L, Rybak MJ, Rude TH, Bradley S, Bukovski S, de la Maria CG, Kanj SS, Korman TM, Marco F, Murdoch DR, Plesiat P, Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton KL, Corey GR, Fowler VG Jr; International Collaboration on Endocarditis-Microbiology Investigator.

J Infect Dis. 2009 Nov 1;200(9):1355-66. PMID: 19811099

 

19. Prevention and treatment of Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative.

Ragle BE, Karginov VA, Bubeck Wardenburg J.

Antimicrob Agents Chemother. 2010 Jan;54(1):298-304. Epub 2009 Oct 5. PMID: 19805564

 

20. Inactivation of staphylococcal virulence factors using a light-activated antimicrobial agent.

Tubby S, Wilson M, Nair SP.

BMC Microbiol. 2009 Oct 5;9:211.PMID: 19804627